# Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy

> **NCT07639086** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Virginia Commonwealth University** · enrollment: 20 (estimated)

## Conditions studied

- Prostate Cancer
- Neuroendocrine Prostate Cancer (NEPC)

## Interventions

- **DRUG:** Sacituzumab Tirumotecan

## Key facts

- **NCT ID:** NCT07639086
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2030-03-31
- **Final completion:** 2032-03-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-08-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07639086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07639086, "Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT07639086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*